Caribou announces positive long-term follow-up for CB-010 in ANTLER Phase 1

Caribou Biosciences, Inc.

Positive long-term follow-up results from dose escalation of ANTLER Phase 1 for CB-010 in relapsed/refractory B-NHL.
CB-010 is an allogeneic anti-CD19 CAR-T cell therapy; study remains ongoing.
Detailed clinical data summary filed as Exhibit 99.1; specific results not provided in the filing excerpt.
Announcement made on July 13, 2023; no financial or regulatory guidance changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.